Article

Advances in Tardive Dyskinesia: A Review of Recent Literature

In the past three years, the U.S. Food and Drug Administration has approved two medications for tardive dyskinesia, contributing to a resurgent interest in recognition, management, and treatment.

This Psychiatric Times® supplement provides a brief review of primarily recent literature on tardive dyskinesia, including signs and symptoms, risk factors and epidemiology, potential mechanisms, and screening and treatment.

Download Supplement

 

Related Videos
lithium
social media
ketamine
media
AI
older person
suicide prevention
McIntyre
John Krystal
Psychiatrists for Mental Health for All
© 2025 MJH Life Sciences

All rights reserved.